Abstract
The following chapter summarizes the results of the phase I and II studies that have been published dealing with radiopeptide therapy in brain tumors. To date, three radiopeptides conjugated with a chelator for radiolabeling with radiometals or labeled directly with 131I have been used in patients. Radiopeptide therapy for brain tumors has to be regarded as experimental. So far, the largest number of patients has been treated with substance P radiolabeled with 90Y, 177Lu, or 213Bi. Besides substance P, the somatostatin analog DOTATOC and the synthetic chlorotoxin TM-601 have been used for this therapy strategy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Beaujouan JC, Torrens Y, Saffroy M et al (2004) A 25 year adventure in the field of tachykinins. Peptides 25:339–357
Beutler D, Avoledo P, Reubi JC et al (2005) Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal Yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. Cancer 103:869–873
Cokgor I, Akabani G, Kuan CT et al (2000) Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18:3862–3872
Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, Müller-Brand J, Mäcke H, Reubi JC, Merlo A (2010) Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]- substance P: a pilot trial. Eur J Nucl Med Mol Imaging 37:1335–1344
Forrer F, Valkema R, Kwekkeboom DJ et al (2007) Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 21:111–129
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003
Hennig IM, Laissue JA, Horisberger U, Reubi JC (1995) Substance-P receptors in human primary neoplasms: tumoral and vascular localization. Int J Cancer 61:786–792
Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911
Kawakami K, Kawakami M, Kioi M et al (2004) Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model. J Neurosurg 101:1004–1011
Kneifel S, Cordier D, Good S et al (2006) Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res 12:3843–3850
Kneifel S, Bernhardt P, Uusijärvi H et al (2007) Individual voxelwise dosimetry of targeted 90Y-labelled substance P radiotherapy for malignant gliomas. Eur J Nucl Med Mol Imaging 34:1388–1395
Laske DW, Youle RJ, Oldfield EH (1997) Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3:1362–1368
Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Maecke HR (2005) Radiolabeled peptides in nuclear oncology: influence of peptide structure and labeling strategy on pharmacology. Ernst Schering Res Found Workshop, pp 43–72
Mamelak AN, Rosenfeld S, Bucholz R et al (2006) Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 24:3644–3650
Merlo A, Jermann E, Hausmann O et al (1997) Biodistribution of 111In-labelled SCN-bz-DTPA-BC-2 MAb following loco-regional injection into glioblastomas. Int J Cancer 71:810–816
Merlo A, Hausmann O, Wasner M et al (1999) Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res 5:1025–1033
Mitrovic B, Martin FC, Charles AC et al (1994) Neurotransmitters and cytokines in CNS pathology. Prog Brain Res 103:319–330
Oertel J, von Buttlar E, Schroeder HW, Gaab MR (2005) Prognosis of gliomas in the 1970s and today. Neurosurg Focus 18:e12
Otte A, Mueller-Brand J, Dellas S et al (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417–418
Rand RW, Kreitman RJ, Patronas N et al (2000) Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6:2157–2165
Riva P, Arista A, Franceschi G et al (1995) Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 55:5952s–5956s
Schumacher T, Hofer S, Eichhorn K et al (2002) Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med Mol Imaging 29:486–493
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1329
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Forrer, F., Cordier, D. (2012). Radiopeptide Therapy of Brain Tumors. In: Baum, R. (eds) Therapeutic Nuclear Medicine. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2012_692
Download citation
DOI: https://doi.org/10.1007/174_2012_692
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-36718-5
Online ISBN: 978-3-540-36719-2
eBook Packages: MedicineMedicine (R0)